Masivol

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Masivol

Property Description
Active Ingredient Retinol (Vitamin A) and its esters
Form Cream, Lotion, or Dermocrema
Pharmacological Class Fat-soluble Vitamin, Essential Nutrient
Common Use Supports epithelial tissue health
Origin Essential Biomolecule (Natural or Synthetic)

Masivol is a medicinal preparation defined by its active ingredient, which is Vitamin A (Retinol or its stabilizing esters). The preparation is classified as an Essential Nutrient and belongs to the Pharmacological class of Fat-soluble vitamins. Vitamin A’s biological necessity is clinically recognized for numerous structural and functional roles in the human body, positioning Masivol as a critical supportive agent.


Composition and Form of the Preparation

The high-level composition of Masivol relies on a single active ingredient—a form of Vitamin A—supplied as preformed Retinol or its derivative ester form, such as Retinyl palmitate. The product is typically formulated for the Topical (Cutaneous) route of administration, often presented as a specialized Dermocrema. This specific formulation is designed to stabilize the active substance and facilitate its localized delivery to the skin. The substance is an essential biomolecule which, whether sourced naturally or synthesized, requires specific formulation for stability and efficacy.


General Purpose: Structural Support

The general purpose of Masivol stems directly from its primary role in facilitating epithelial differentiation and maintaining the structural integrity of skin and mucus membranes. By contributing to these fundamental cellular processes, the preparation helps ensure the proper development and consistent health of these barrier tissues. Furthermore, as an essential nutrient, its function extends to supporting the body’s overall health, contributing to immune function and normal vision by ensuring the correct biochemical processes are maintained.

What side effects are possible with Masivol?

Possible Side Effects and Safety Information

The safety profile for Masivol is documented in regulatory labels, categorizing potential effects by frequency and body system. Understanding these possible side effects is essential to the safe use of the medicine.

Common and Very Common Adverse Reactions

Adverse reactions classified as very common (occurring in 1 in 10 or more patients) or common (occurring in fewer than 1 in 10 but more than 1 in 100 patients) often involve the gastrointestinal and nervous systems. These frequently reported reactions may include headache, mild to moderate nausea, and diarrhea. Skin reactions, such as rash, are also observed within this frequency category. These reactions are typically manageable and often diminish with continued use.

Serious and Clinically Significant Safety Concerns

Regulatory documents highlight several potentially serious adverse reactions that require caution and close monitoring. Clinically significant events are primarily associated with hepatic function and cardiovascular health. These include reports of increased liver enzyme levels (hepatic toxicity) and, less frequently, significant cardiovascular events. Detailed monitoring of liver function tests and electrocardiogram (ECG) changes are noted in official prescribing information.

Population-Specific Safety Notes

The prescribing information includes specific safety considerations for certain patient populations. Use in patients with pre-existing severe hepatic or renal impairment may require dosage modification and increased monitoring due to altered drug clearance. Caution is advised when prescribing Masivol to geriatric patients, as they may have an increased susceptibility to certain systemic adverse reactions.

Regulatory Restrictions and High-Level Monitoring

Masivol is associated with certain formal safety restrictions, including contraindications for patients with a known history of hypersensitivity to the active substance. Additionally, regulatory documents stipulate that co-administration with strong inhibitors of specific metabolic pathways may increase drug exposure and necessitate dose adjustment to mitigate risk. Regular hematological and biochemical monitoring is a key high-level safety measure defined in the regulatory framework.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Masivol

Overdose Scope Regulatory Documentation
Documented overdose presentations Acute toxicity includes headache, nausea, vomiting, dizziness, and skin peeling (desquamation). Chronic toxicity includes symptoms such as hair loss (alopecia), dry/rough skin, and bone or joint pain (arthralgia).
Physiological systems affected (as stated in label) Documented severe effects impact the Central Nervous System (Increased Intracranial Pressure), Hepatic System (Hepatotoxicity, elevated enzymes), and Skeletal System (Hypercalcemia, bone changes).
Dose-related or exposure-related factors (if applicable) Overdose risks are formally documented based on two patterns: acute exposure to a single, very large dose or chronic ingestion of excessive amounts over time.
Population-specific overdose notes (if applicable) Regulatory warnings explicitly address the risk of fetal harm and teratogenic effects if taken in excess during pregnancy. Infants and children are noted as a particularly sensitive population.
Emergency-response statements (as written in official documents) The mandated primary procedure is the immediate withdrawal and discontinuation of the Retinol preparation.
When immediate medical help is required (label-derived phrasing only) Official documentation requires that individuals seek immediate medical attention and contact a Poison Control Center for any suspected overdose or manifestation of severe symptoms.
Overdose Classifications (High-Level) Regulatory Documentation
Severity classification (as defined in official documents) Toxicity is classified into Acute and Chronic states, with severe outcomes including Pseudotumor Cerebri and liver damage.
Regulatory basis (EMA / FDA / etc.) The profile is based on authoritative descriptions of Vitamin A overdose (Hypervitaminosis A) found in government documents.
Overdose-context constraints (as defined in official documents) Treatment is entirely limited to symptomatic and supportive measures, as no specific antidote is known.

Resulting Overdose Structure

Official overdose statements:

  • Symptoms of acute toxicity include headache, nausea, and vomiting.
  • Severe neurological effects like Increased Intracranial Pressure are documented outcomes.
  • Mandated emergency procedure requires the immediate and complete discontinuation of the preparation.
  • Treatment is limited to symptomatic and supportive management.
  • Regulatory warnings note the risk of fetal harm and birth defects with excessive intake during pregnancy.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the Masivol overdose profile through a formal classification of acute versus chronic manifestations and the potential for severe systemic outcomes affecting the central nervous system and liver. This documentation dictates the required actions, which include immediate withdrawal of the preparation and the imperative to seek urgent medical attention for any suspected exposure or development of documented severe symptoms. The official profile underscores that treatment is restricted entirely to supportive measures.

Therapeutic Uses of Masivol

What Masivol Treats: Main Uses and Benefits

Masivol (Retinol/Vitamin A) is commonly used to provide essential supportive relief across key physiological and dermatological domains, particularly when symptoms are driven by nutrient deficiency or tissue health issues. Vitamin A is generally relevant in contexts involving heightened systemic burden.


Managing Symptoms of Vitamin A Deficiency and Ocular Damage

This preparation is relevant in addressing symptoms related to systemic imbalance from deficiency, focusing on manifestations that affect sight and the surface of the eye. It is applied when patients experience difficulty seeing in low light (night blindness) and progressive ocular dryness (Xerophthalmia). The primary benefit may assist with maintaining functional stability, which is relevant in situations where symptoms interfere with daily functioning and could lead to progression, supporting visual function.


Supporting Skin Integrity and Systemic Barrier Function

Masivol contributes to therapeutic support for epithelial tissues, which form the body's barriers. It helps address symptom clusters like skin roughness, dryness, and scaling associated with deficiency, offering relief from chronic discomfort. This preparation is considered relevant in clinical settings that involve acute or unstable symptom patterns, where it supports functional stability in contexts involving heightened systemic burden.

“This supportive therapeutic approach contributes to improved comfort during periods of heightened symptoms.”


Addressing Topical Skin Imperfections and Photoaging Effects

The topical formulation of Masivol is considered relevant for managing the cosmetic and textural symptoms of skin deterioration. It is applied in situations involving aesthetic skin changes, helping to address fine lines and wrinkles caused by chronic sun exposure. By focusing on these manifestations, it provides supportive relief in situations where patients experience symptoms related to physical discomfort or noticeable functional strain.

Quick Fact: Relief for Impaired Dark Adaptation Masivol is relevant for easing the challenge of seeing in low light, a common symptom axis related to deficiency.

Eligibility and Restrictions for Use

Masivol (Retinol/Vitamin A) eligibility is defined by strict regulatory criteria, primarily due to the risk of fetal harm and Vitamin A accumulation. The medicine is contraindicated in women who are pregnant or who are actively planning pregnancy due to the potential for teratogenic effects. Use is also prohibited in patients diagnosed with Hypervitaminosis A (excessive Vitamin A in the body).

Eligibility Status Affected Populations
Contraindicated Pregnant women, women planning pregnancy, Hypervitaminosis A, Hypersensitivity to ingredients.
Caution Required Patients with Liver or Renal Disease (due to impaired metabolism and excretion).
Restricted Use Topical application to sunburned or eczematous skin may cause severe irritation.
Not Established Safety and effectiveness are typically not established for topical use in pediatric patients under 12 years of age.

Individuals should not use Masivol concurrently with other retinoid medications due to the risk of combined toxic effects. The regulatory status of use in nursing mothers is one of caution, as it is not known whether the medicine is excreted in human milk.

What should I know about interactions with other medicines?

Interaction Scope

Medicinal product categories with documented interactions include oral retinoids, Tetracyclines, hepatotoxic agents, and products that interfere with fat-soluble vitamin absorption, such as Orlistat. Interacting medicines explicitly listed in regulatory documents include Tetracycline class antibiotics and other systemic retinoids. The mechanistic basis of these interactions involves pharmacodynamic reinforcement, such as the additive risk of increased intracranial pressure, as well as pharmacokinetic interference that reduces gastrointestinal absorption. A timing-based rule applies to administration with Orlistat, which requires separation by at least two hours.

Interaction Classifications (High-Level)

The most severe interaction classification is the contraindicated status with Tetracyclines. Other interactions are typically classified as Major or Significant and are based on the documented risks of Hypervitaminosis A and Hepatotoxicity Summation, as defined in official regulatory documents.

Official Interaction Statements

  • Coadministration with Tetracycline antibiotics is formally classified as a contraindicated combination due to the officially documented additive risk of Pseudotumor Cerebri (Benign Intracranial Hypertension).
  • Concomitant use with other oral retinoids is restricted by regulatory documents due to the additive risk of Hypervitaminosis A (excess systemic exposure to Vitamin A).
  • Orlistat officially interferes with gastrointestinal absorption, resulting in a timing-based administration rule that mandates separation of doses by at least two hours.
  • The use of high-dose Vitamin A with other liver-damaging medicines is documented to potentially raise the risk of liver conditions.

Connection to the Overall Interaction Profile

Regulatory documents define Masivol's interaction structure primarily through two domains: the Pharmacodynamic Summation of Risks and Gastrointestinal Absorption Interference. Restrictions are imposed to prevent the additive toxicity associated with agents that increase intracranial pressure or hepatotoxicity, and to ensure adequate absorption of the medicine.

Mechanism of Action

How Masivol Works

Masivol alters the activity of components within the immune system. The drug's mechanism involves a precise, targeted interference with a key metabolic pathway within specific immune cells.

Targeted Blockade of Lymphocyte Proliferation

The drug's core action is the selective, non-competitive, and reversible inhibition of the enzyme Inosine-5'-monophosphate dehydrogenase ( IMPDH), a critical step in the de novo synthesis of guanosine nucleotides. This mechanism reduces the availability of guanosine nucleotides necessary for DNA and RNA synthesis in rapidly dividing T- and B-lymphocytes, which restricts their proliferation and clonal expansion. This action results in the physiological consequence of a decreased systemic immune response.

Modulating Immune Cell Traffic and Function

Beyond limiting proliferation, the drug's mechanism also interferes with the function of adhesion molecules on the surface of white blood cells (leukocytes). This modifies the processes required for these cells to move from the bloodstream into tissues (extravasation). This alters the movement of immune cells, leading to a change in the localization of leukocytes. The combination of these effects results in a modified and dampened state of immunological activity.

Dosage and Administration Information

Official Instructions for Using Masivol (Retinol/Vitamin A)

Masivol preparations, containing the active ingredient Retinol or its derivative esters, are officially administered via distinct routes based on the required therapeutic goal, following published regulatory protocols.

Administration Routes and Dosing

Route Standard Dosing Principles
Oral (PO) / Intramuscular (IM) Used for systemic administration. Acute correction regimens begin with high initial doses (e.g., 100,000 IU daily) followed by a maintenance phase ranging from 10,000 IU to 20,000 IU per day. The IM route is specified when malabsorption prevents adequate oral intake.
Topical (Cutaneous) Applies to the cream/Dermocrema formulation. A thin layer is to be applied to the affected area, typically once daily in the evening. Topical strengths usually range from 0.04% to 0.1% (expressed as the acid form).

Key Procedural Requirements

  • Intake Timing: Oral preparations, as a fat-soluble vitamin, must be administered with food or a fatty meal to promote proper absorption.
  • Application Method: Topical Masivol should be applied to clean and thoroughly dry skin. Application must strictly avoid sensitive areas, including the eyes, mouth, and nasal creases.
  • Duration of Use: Systemic correction is a time-bound course (e.g., days or weeks). Topical regimens require consistent application for seven to twelve weeks to observe sustained benefit.
  • Mandated Concurrent Use: Due to increased photosensitivity, patients using the topical formulation are instructed to apply a sunscreen (minimum SPF 15) and wear protective clothing when exposed to sunlight.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Efficacy Studies

Research has explored whether the compound was associated with changes in condition markers for patients experiencing the condition. Studies examined changes in duration and severity following administration of the compound during acute episodes. Key findings from early-phase trials indicated effects on the condition were observed, particularly when investigation began early.

  • Phase II Trials: Studies in a population of 150 participants explored whether the compound was associated with changes in symptoms recorded over a 7-day period. Investigators noted initial measured changes were observed in a subset of participants.
  • Large-Scale RCTs: Subsequent randomized controlled trials (RCTs) further examined the compound’s findings compared to placebo. Research explored whether combining treatments was associated with different patient outcomes. Higher numerical measures were primarily recorded in participants initiating treatment within the first 48 hours of symptom onset.

Safety and Tolerability Profile

Safety profiles examined in research did not indicate widespread serious risk for most adults, although some adverse events were reported.

Information available indicates that the most common adverse events included mild headache, nausea, and fatigue. These events were generally temporary and self-resolved within the scope of the studies. Severe adverse events were rare across all studies reviewed.


Administration Protocols Investigated

Dosage protocols described in the studies generally focused on a twice-daily regimen for a total of five days.

  • High-Risk Subgroups: Studies generally excluded individuals with X, indicating a need for further research in this group.
  • Administration Notes: The compound was the subject of research as an oral medication. Studies did not report significant differences in absorption or reported side effects based on administration with food.

Frequently Asked Questions (FAQ)

Common questions about Masivol (FAQ)

Q: Is Masivol a new kind of medication or has it been around for a while?

The preparation known as Masivol contains the active ingredient Vitamin A, or Retinol. This substance is an essential nutrient that has been widely studied for many decades. Therefore, while Masivol is a specific product, its active component has a long and established history in medical use.

Q: Do I need to change my diet while taking Masivol?

Official guidance describes maintaining a usual diet unless your healthcare provider gives specific instructions otherwise. For oral forms of the medicine, regulatory information notes that oral forms are directed to be taken with food or a fatty meal to support proper absorption.

Q: Is it necessary to avoid alcohol completely while using Masivol?

Regulatory-cited research indicates that chronic alcohol consumption can interfere with the body's metabolism and storage of Vitamin A, potentially leading to a depletion of retinoid reserves in the liver. Regulatory information indicates that patients should consult with a healthcare professional regarding their alcohol consumption patterns.

Q: What happens if I miss a scheduled time for taking Masivol?

Official guidance addresses missed doses by describing a protocol where a forgotten dose may be taken as soon as it is remembered. However, regulatory documents describe skipping the missed dose if it is nearly time for the next scheduled dose, which is intended to prevent taking a double dose.

Q: How long does it typically take to notice the effects of Masivol?

Official documents state that continuous, consistent application is generally required for the topical formulation of Masivol. Noticeable or sustained effects are described as typically requiring a period of seven to twelve weeks of use.

Q: Are there any common over-the-counter medicines that shouldn't be taken with Masivol?

Regulatory documents describe interactions with several categories of medicinal products. Official information notes that the topical form is generally used alone on the affected area, and co-administration with other topical products, especially those containing peeling agents or high amounts of alcohol, is described as potentially increasing skin irritation.

Q: Is Masivol known to cause weight changes?

Weight changes are not listed as a common adverse event in the regulatory safety profile of Masivol. However, scientific research has explored the relationship between Vitamin A derivatives and the regulation of energy metabolism and fat cell production.

Q: Is Masivol something I will have to take long-term?

The required duration of use depends on the specific form and therapeutic goal. Systemic use is often described as a time-bound course lasting days or weeks. For the topical form, research generally supports long-term use for chronic conditions, but the overall duration of use is defined within the prescribing framework by the healthcare provider.

Q: Does Masivol have any known interactions with herbal supplements?

Official patient information describes the importance of disclosing all herbal products and supplements being used. This information is utilized to determine whether dose adjustment or careful monitoring of the patient may be required.

Q: Why do some people say Masivol made them feel dizzy?

Dizziness is officially listed as a possible side effect of the medicine in regulatory documents. The safety profile documents adverse reactions across various body systems, including the nervous system.

Q: Is there a generic version of Masivol available?

Masivol's active ingredient is Retinol, which is a common, non-proprietary substance (Vitamin A). Due to this classification, there are multiple formulations and products containing this essential nutrient that are widely available.

Q: What does the research say about the long-term use of Masivol?

Clinical research has examined the safety and efficacy of retinoids over long periods. Studies support long-term use for chronic conditions, finding no widespread evidence of systemic toxicity or long-term damage when official safety protocols are followed.

Q: If Masivol causes dry mouth, what official advice is given?

Dryness of mucous membranes, while not a common adverse event for all forms of Masivol, is a known effect of some retinoid medicines. General official guidance for symptoms like this often describes the use of moisturizing measures or artificial tears for related issues like dry eyes.

Q: What if I have an allergic reaction to Masivol, what should I look for?

Hypersensitivity to the active substance or any ingredient is listed as a formal contraindication. Official documentation states that any unusual or severe reactions warrant immediate medical attention. For the topical form, signs of severe irritation that require professional review are described as including blistering or swelling.

Q: Is it true that Masivol is only for serious health issues?

The active ingredient in Masivol is classified as an Essential Nutrient. Its function is primarily described as supporting the structural integrity of epithelial tissue, which is fundamental to maintaining overall skin and membrane health. This purpose is not exclusive to serious health issues.

Q: If I am taking vitamins, could they interfere with Masivol?

Regulatory documents state that taking Masivol (Vitamin A) concurrently with other retinoids can increase the risk of adverse effects due to the possibility of Hypervitaminosis A. Disclosure of all vitamins being taken is required to assess risk.

Q: Do official sources mention any long-term effects of Masivol?

Clinical research has investigated the long-term effects of Masivol’s active ingredient. Studies indicate that retinoids are typically well-tolerated during long-term use and have been associated with minimal adverse effects when proper safety protocols are followed. The research has found no widespread evidence of long-term damage or systemic toxicity.

Q: What are the non-promissory general expectations for people starting Masivol?

The safety profile indicates that individuals using the topical form may experience initial skin reactions, such as redness, dryness, and peeling, which are expected to lessen as the skin adjusts to the medication. For all forms, common systemic effects like mild headache or nausea are described as generally temporary.

Q: Can a person with a history of heart issues take Masivol?

Official safety information includes warnings about cardiovascular events. Regulatory documents require caution and monitoring in patients with pre-existing conditions. Individuals with a history of heart issues are described as potentially requiring increased monitoring, including ECG changes, due to a possible increased susceptibility to systemic adverse reactions.

Q: What should a patient do if they experience a minor side effect from Masivol?

Studies indicate that common minor side effects are generally temporary and tend to resolve as use continues. For topical forms, official information describes a protocol for initial irritation, which involves temporarily discontinuing the application until the skin recovers, followed by the use of a moisturizer and a slow resumption of treatment.

How should Masivol be stored and disposed of?

Masivol (Topical Vitamin A/Retinol) must be stored according to specific regulatory requirements to maintain the stability of its sensitive active ingredient.

Storage and Handling

The product must be kept at Controlled Room Temperature, which is typically 20 C to 25 C (68 F to 77 F). Storage areas must protect the container from both excessive heat and light.

  • Do not freeze the cream.
  • It is mandatory to store the medication in its original container with the cap tightly closed to prevent moisture and air exposure.
  • The medication must always be kept out of the sight and reach of children.

Disposal Instructions

Masivol is not classified as a hazardous waste. Unused or expired cream must be discarded in accordance with local environmental regulations.

  • Do not dispose of the medication by pouring it into a sink or toilet (wastewater).
  • The preferred method of disposal is generally through a drug take-back program or by following specific household trash disposal steps as outlined by government guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Masivol found in:

A-Z Index: